 Leukemia, Myeloid, Acute
"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Descriptor ID |
D015470
|
| MeSH Number(s) |
C04.557.337.539.275
|
| Concept/Terms |
Leukemia, Myeloid, Acute- Leukemia, Myeloid, Acute
- Acute Myeloid Leukemia
- Acute Myeloid Leukemias
- Leukemias, Acute Myeloid
- Myeloid Leukemias, Acute
- ANLL
- Leukemia, Acute Myelogenous
- Leukemia, Acute Myeloid
- Leukemia, Myeloblastic, Acute
- Leukemia, Myelocytic, Acute
- Leukemia, Myelogenous, Acute
- Leukemia, Nonlymphoblastic, Acute
- Leukemia, Nonlymphocytic, Acute
- Myeloblastic Leukemia, Acute
- Acute Myeloblastic Leukemia
- Acute Myeloblastic Leukemias
- Leukemia, Acute Myeloblastic
- Leukemias, Acute Myeloblastic
- Myeloblastic Leukemias, Acute
- Myelocytic Leukemia, Acute
- Acute Myelocytic Leukemia
- Acute Myelocytic Leukemias
- Leukemia, Acute Myelocytic
- Leukemias, Acute Myelocytic
- Myelocytic Leukemias, Acute
- Myelogenous Leukemia, Acute
- Myeloid Leukemia, Acute
- Nonlymphoblastic Leukemia, Acute
- Acute Nonlymphoblastic Leukemia
- Acute Nonlymphoblastic Leukemias
- Leukemia, Acute Nonlymphoblastic
- Leukemias, Acute Nonlymphoblastic
- Nonlymphoblastic Leukemias, Acute
- Nonlymphocytic Leukemia, Acute
- Acute Nonlymphocytic Leukemia
- Acute Nonlymphocytic Leukemias
- Leukemia, Acute Nonlymphocytic
- Leukemias, Acute Nonlymphocytic
- Nonlymphocytic Leukemias, Acute
- Acute Myelogenous Leukemia
- Acute Myelogenous Leukemias
- Leukemias, Acute Myelogenous
- Myelogenous Leukemias, Acute
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".
- Leukemia, Myeloid, Acute
- Leukemia, Basophilic, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Erythroblastic, Acute
- Leukemia, Mast-Cell
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Monocytic, Acute
- Leukemia, Promyelocytic, Acute
This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 6 | 1 | 7 | | 2005 | 2 | 0 | 2 | | 2006 | 4 | 1 | 5 | | 2007 | 4 | 1 | 5 | | 2008 | 5 | 0 | 5 | | 2009 | 3 | 3 | 6 | | 2010 | 7 | 1 | 8 | | 2011 | 9 | 0 | 9 | | 2012 | 8 | 2 | 10 | | 2013 | 15 | 1 | 16 | | 2014 | 10 | 2 | 12 | | 2015 | 13 | 1 | 14 | | 2016 | 15 | 5 | 20 | | 2017 | 23 | 3 | 26 | | 2018 | 28 | 6 | 34 | | 2019 | 30 | 1 | 31 | | 2020 | 21 | 1 | 22 | | 2021 | 32 | 2 | 34 | | 2022 | 30 | 1 | 31 | | 2023 | 30 | 0 | 30 | | 2024 | 22 | 5 | 27 | | 2025 | 21 | 0 | 21 | | 2026 | 17 | 0 | 17 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
Wang ES, Erba H, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano ND, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Oct 01; 148(14):1775-1788.
-
Zheng DJ, Khuong L, Aftandilian C, Bona K, Caywood EH, Elgarten CW, Fisher BT, Gathers CL, Ghosh T, Gramatges MM, Hettinger G, Henry MR, Huang YV, Li Y, Maloney K, Mian A, Miller TP, Modi A, Mody R, Myers RM, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD. Race and Ethnicity and Overall Survival in Pediatric Acute Myeloid Leukemia. JAMA Netw Open. 2026 08 03; 9(8):e2628602.
-
Espinoza-Gutarra MR, Jarret B, Wang X, Afghahi A, Bae S. Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2. Cancer Rep (Hoboken). 2026 08; 9(8):e70657.
-
Garcia JS, Desai P, Zeidner JF, Wolach O, LeBlanc TW, Abedin S, Vachhani P, Sweet K, Moshe Y, Pollyea DA, Lai C, Levitz D, Nachmias B, Mozessohn L, Xavier M, Zuckerman T, Konopleva M, Chen EC, Stahl M, Xu Y, Bui CN, Miu K, Schmidt X, Grunspan M, Lin CW, Ma E, Montez M, Guérin A, Burne R, Easson K, Levesque-Leroux M, Baraka E, Goldberg AD. Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study. Leuk Lymphoma. 2026 Sep; 67(11):2282-2294.
-
Pastrana CC, Nonavinkere Srivatsan S, Alberti MO, Hossan T, Ahmed T, Shao J, Chavez M, Grieb S, Padro JI, Paul DM, George DR, Patil A, Rai S, Graubert TA, Bailis JM, You Z, Walter MJ. Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage. Cancer Res. 2026 07 15; 86(14):3537-3553.
-
Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, ?ucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 09; 44(25):2422-2434.
-
Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257.
-
Pollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt VR, Fathi AT, Fedorov K, Foran JM, Gojo I, Goldberg A, Hall AC, Jonas BA, Levine MR, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival ME, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone RM, Thota S, Uy GL, Walker A, Wang E, Awotiwon A, Roth SL, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. J Natl Compr Canc Netw. 2026 Jun; 24(6):222-229.
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
-
De León AG, An JJ, Gourgioti G, Xie Y, Zhong J, Wu EQ, Ariza JG, Cheng LJ. Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico. Cancer Treat Res Commun. 2026; 48:101229.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|